Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results

Rhea-AI Summary

Alnylam Pharmaceuticals to report Q3 2023 financial results on November 2nd

Positive

• Alnylam Pharmaceuticals will report its financial results for the third quarter ending September 30, 2023 on November 2, 2023.
• Management will provide an update on the company and discuss third quarter 2023 results as well as expectations for the future via a conference call.
• A live audio webcast of the call will be available on the Investors section of the company's website.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2, 2023, before the U.S. financial markets open.

Management will provide an update on the Company and discuss third quarter 2023 results as well as expectations for the future via conference call on Thursday, November 2, 2023 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BI29582eb5fd274b758554baecef8f03fa. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.

A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231019367164/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When will Alnylam Pharmaceuticals report its Q3 2023 financial results?

Alnylam Pharmaceuticals will report its financial results for the third quarter ending September 30, 2023 on November 2, 2023.

How can I access the conference call?

To access the call, please register online at the provided link.

Will there be a replay of the conference call?

Yes, a replay of the call will be available two hours after the call and archived on the same web page for six months.

Where can I find the live audio webcast of the conference call?

A live audio webcast of the call will be available on the Investors section of the company's website.

Will there be an archived webcast of the conference call?

Yes, an archived webcast will be available on the Alnylam website approximately two hours after the event.